Gradalis’ GRAD1405 bi-shRNAi Breakthrough: A Triumphant Stride Against Drug-Resistant Cancers
In a significant leap forward in the ongoing battle against drug-resistant cancers, Gradalis, a forefront player in personalized cancer immunotherapy, has unveiled promising results for its innovative candidate, GRAD1405 bi-shRNAi.…